Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBITDA: 2012-2024

Historic EBITDA for Neurogene (NGNE) over the last 11 years, with Dec 2024 value amounting to -$82.6 million.

  • Neurogene's EBITDA fell 7.29% to -$23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.3 million, marking a year-over-year decrease of 28.33%. This contributed to the annual value of -$82.6 million for FY2024, which is 48.62% down from last year.
  • Latest data reveals that Neurogene reported EBITDA of -$82.6 million as of FY2024, which was down 48.62% from -$55.6 million recorded in FY2023.
  • Neurogene's EBITDA's 5-year high stood at -$55.6 million during FY2023, with a 5-year trough of -$82.6 million in FY2024.
  • Moreover, its 3-year median value for EBITDA was -$56.5 million (2022), whereas its average is -$64.9 million.
  • As far as peak fluctuations go, Neurogene's EBITDA rose by 1.65% in 2023, and later slumped by 48.62% in 2024.
  • Neurogene's EBITDA (Yearly) stood at -$56.5 million in 2022, then rose by 1.65% to -$55.6 million in 2023, then tumbled by 48.62% to -$82.6 million in 2024.